Abstract
A total of forty patients participated in an open, randomized study to compare the efficacy and toleration of a single dose of topical tioconazole 6% vaginal ointment with 5 days treatment of systemic ketoconazole (400 mg/day) in patients with symptomatic vaginal candidal infection. Disease in patients of both treatment groups was effectively eradicated after 5 weeks of therapy. Symptoms of patients receiving topical therapy responded more quickly than those of patients receiving oral therapy. Side-effects were more prevalent with ketoconazole systemic therapy. Overall, topical therapy with tioconazole was preferred over systemic ketoconazole therapy for these women with symptomatic vulvovaginitis due to Candida albicans.
Get full access to this article
View all access options for this article.